Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Zangari · SciRah

Researcher profile · Semantic Scholar

M. Zangari

Share profile

M. Zangari — researcher profile on SciRah

h-index: 68
Works: 461
Citations: 18K

Most-cited papers

Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
F. Mazahreh, L. Mazahreh, C. Schinke, S. Thanendrarajan +5 more
2022Blood Advances136 citations Open access
Semantic Scholar
The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
E. Boyle, S. Deshpande, R. Tytarenko, C. Ashby +19 more
2021Nature Communications107 citations Open access
Semantic Scholar
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
M. Mohan, Jorge Monge, Nishi Shah, Danny Luan +17 more
2024Blood Cancer Journal84 citations Open access
Semantic Scholar
The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
L. Rasche, C. Schinke, Francesco Maura, M. Bauer +12 more
2022Nature Communications65 citations Open access
Semantic Scholar
Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
R. Al-Qazaqi, C. Schinke, S. Thanendrarajan, M. Zangari +5 more
2022JAMA Network Open60 citations Open access
Semantic Scholar
The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
Lindsay Hammons, A. Szabo, A. Janardan, Vineel Bhatlapenumarthi +16 more
2023Haematologica58 citations Open access
Semantic Scholar
Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
C. Schinke, A. Poos, M. Bauer, L. John +13 more
2022Blood Advances58 citations Open access
Semantic Scholar
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
Yan Cheng, Fumou Sun, Daisy V. Alapat, Visanu Wanchai +16 more
2024Blood Cancer Journal47 citations Open access
Semantic Scholar
Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor–T Cell Therapy for Hematological Malignant Neoplasms
Samer al Hadidi, C. Schinke, S. Thanendrarajan, M. Zangari +1 more
2022JAMA Network Open43 citations Open access
Semantic Scholar
Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level
L. John, A. Poos, A. Brobeil, C. Schinke +34 more
2023Nature Communications41 citations Open access
Semantic Scholar
Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
M. Mohan, A. Szabo, Heloise Cheruvalath, Anna Clennon +19 more
2025Blood Cancer Journal37 citations Open access
Semantic Scholar
Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma
M. Mohan, A. Szabo, Anannya Patwari, Jean Esselmann +18 more
2024Bone Marrow Transplantation26 citations
Semantic Scholar
Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study
M. Mohan, Nishi Shah, Danny Luan, Jorge Monge +17 more
2023Blood24 citations Open access
Semantic Scholar
Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy
Samer al Hadidi, A. Szabo, Jean Esselmann, Lindsay Hammons +16 more
2022Bone Marrow Transplantation24 citations
Semantic Scholar
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
Yan Cheng, Fumou Sun, Daisy V. Alapat, Visanu Wanchai +25 more
2023Cell Reports Medicine20 citations Open access
Semantic Scholar
CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
Dong-Zheng Gai, Jin-Ran Chen, J. P. Stewart, I. Nookaew +17 more
2022Journal of Clinical Investigation20 citations Open access
Semantic Scholar
Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab
S. Naqvi, Asis Shrestha, Marah Alzu'bi, Jawad Alrawabdeh +5 more
2024eJHaem14 citations Open access
Semantic Scholar
Corneal toxicity with belantamab mafodotin: Multi‐institutional real‐life experience
M. Mohan, Lisa E. Rein, N. Thalambedu, Y. Ogunsesan +19 more
2022American journal of hematology/oncology14 citations Open access
Semantic Scholar
Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
Lakshmi Yarlagadda, Sravani Gundarlapalli, R. Parikh, Reid D. Landes +13 more
2021Cancers14 citations Open access
Semantic Scholar
Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma
T. Patel, Ramya Bachu, Trilok Shrivastava, Jawad Alrawabdeh +11 more
2024Clinical Hematology International12 citations Open access
Semantic Scholar
Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS
Wan-Cheng Guo, Anne Zhan, David E. Mery, M. Munshi +6 more
2023Blood Advances12 citations Open access
Semantic Scholar
Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma-Challenges and Potential Solutions.
Samer al Hadidi, M. Zangari, F. van Rhee
2022JAMA Oncology12 citations
Semantic Scholar
A gene signature can predict risk of MGUS progressing to multiple myeloma
Fumou Sun, Yan Cheng, Jun Ying, David E. Mery +17 more
2023Journal of Hematology & Oncology11 citations Open access
Semantic Scholar
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
Samer al Hadidi, O. Ababneh, C. Schinke, S. Thanendrarajan +12 more
2023Blood Advances11 citations Open access
Semantic Scholar
Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study
Heloise Cheruvalath, Anna Clennon, Asis Shrestha, A. Szabo +19 more
2024Blood10 citations
Semantic Scholar
Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
M. Mohan, Z. Gong, T. Ashby, Samer al Hadidi +9 more
2023Cancer10 citations
Semantic Scholar
Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
Kristin T Larsen, H. Spencer, M. Mohan, Clyde Bailey +21 more
2022Journal of Clinical Medicine9 citations Open access
Semantic Scholar
High‐risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse
E. Boyle, A. Rosenthal, Yan Wang, P. Farmer +14 more
2021British Journal of Haematology9 citations Open access
Semantic Scholar
Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups
E. Boyle, A. Rosenthal, H. Ghamlouch, Yan Wang +17 more
2021Leukemia8 citations Open access
Semantic Scholar
Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma
Bhavesh Mohan Lal, Marah Alzubi, Jawad Alrawabdeh, J. Shaughnessy +7 more
2024Blood Advances7 citations Open access
Semantic Scholar
Variability of definition of high‐risk multiple myeloma across phase III clinical trials
F. Abu Za'nouneh, O. Ababneh, C. Schinke, S. Thanendrarajan +5 more
2023eJHaem7 citations Open access
Semantic Scholar
Bone remineralization Of Lytic Lesions in Multiple Myeloma --The Arkansas Experience
M. Mohan, M. Kumar, Rohan S. Samant, R. Van Hemert +10 more
2021Bone7 citations Open access
Semantic Scholar
Sequential Imaging with Diffusion-Weighted Whole-Body MRI (DW-MRI) and PET-CT Identifies Patients at High Risk of Relapse in Multiple Myeloma
C. Schinke, L. Rasche, C. Ashby, R. Van Hemert +10 more
2023Blood6 citations Open access
Semantic Scholar
Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma
M. Mohan, Sravani Gundarlapalli, A. Szabo, N. Yarlagadda +15 more
2022American journal of hematology/oncology6 citations
Semantic Scholar
Under-representation of black patients with multiple myeloma in studies supporting International Myeloma Working Group guidelines.
Suhib Fahmawi, C. Schinke, S. Thanendrarajan, M. Zangari +4 more
2022Journal of Cancer Policy6 citations Open access
Semantic Scholar
Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imaging
C. Schinke, L. Rasche, Cody Ashby, R. Van Hemert +10 more
2025Blood Advances5 citations Open access
Semantic Scholar
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols: A Secondary Analysis of 3 Clinical Trials.
Samer al Hadidi, O. Ababneh, C. Schinke, S. Thanendrarajan +11 more
2025JAMA Oncology5 citations
Semantic Scholar
Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort
Metodi Balev, Nishi Shah, Mansi R. Shah, Anannya Patwari +19 more
2024Blood5 citations
Semantic Scholar
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
Samer al Hadidi, O. Ababneh, C. Schinke, S. Thanendrarajan +12 more
2024Blood Advances5 citations Open access
Semantic Scholar
BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions
Fumou Sun, Yan Cheng, Jin-Ran Chen, Visanu Wanchai +11 more
2023Journal of Clinical Investigation5 citations Open access
Semantic Scholar
EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression
W. Ling, Sarah K. Johnson, Syed J Mehdi, Daisy V. Alapat +6 more
2023Cancers5 citations Open access
Semantic Scholar
Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience
M. Mohan, M. Becnel, U. Shah, Hua-jiang Dong +28 more
2022American journal of hematology/oncology5 citations Open access
Semantic Scholar
First‐ versus second‐generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta‐analysis
H. Abushukair, S. Syaj, O. Ababneh, A. Qarqash +5 more
2022American journal of hematology/oncology5 citations
Semantic Scholar
Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
Wancheng Guo, Yi-Hao Zhan, David E. Mery, E. R. Siegel +15 more
2024Blood Cancer Journal4 citations Open access
Semantic Scholar
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation
Wancheng Guo, C. Strouse, David E. Mery, Eric R. Siegel +17 more
2024Cancers4 citations Open access
Semantic Scholar
Prognostic Value of Ferritin in ASCT MM Patients: Integration with GEP Models and ISS Series Systems
Wancheng Guo, David E. Mery, Eric R. Siegel, Fumou Sun +12 more
2023Blood4 citations Open access
Semantic Scholar
Growth and dormancy control of myeloma cells by mesenchymal stem cells.
S. Mehdi, K. Ghatak, W. Ling, Sarah K. Johnson +7 more
2023Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis4 citations Open access
Semantic Scholar
Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma
M. Mohan, A. Szabo, N. Yarlagadda, Sravani Gundarlapalli +9 more
2021American journal of hematology/oncology4 citations Open access
Semantic Scholar
Application of Stem Cell Boost for Immune Effector Cell Associated Hematotoxicity (ICAHT) Following BCMA Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma (MM)
Kritika Yadav, T. Patel, Ramya Bachu, Jean Esselmann +17 more
2024Blood3 citations
Semantic Scholar
Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma
Samer al Hadidi, O. Ababneh, C. Schinke, Sharmilan Thanendrarajan +9 more
2024American journal of hematology/oncology3 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

C. Schinke×48
Invite
C. Schinke — researcher profile on SciRah
S. Thanendrarajan×41
Invite
S. Thanendrarajan — researcher profile on SciRah
Samer al Hadidi×38
Invite
Samer al Hadidi — researcher profile on SciRah
F. van Rhee×34
Invite
F. van Rhee — researcher profile on SciRah

×17

Invite

M. Mohan — researcher profile on SciRah

Daisy V. Alapat×14

Invite

Daisy V. Alapat — researcher profile on SciRah

J. Shaughnessy×14

Invite

J. Shaughnessy — researcher profile on SciRah

Clyde Bailey×13

Invite

Clyde Bailey — researcher profile on SciRah

Guido J. Tricot×12

Invite

Guido J. Tricot — researcher profile on SciRah

Invite

F. Zhan — researcher profile on SciRah

Invite

B. Dhakal — researcher profile on SciRah

Fritz Van Rhee×11

Invite

Fritz Van Rhee — researcher profile on SciRah